Company Name: |
Amplia Therapeutics Limited (ACN 165 160 841) |
|
Business Description: |
Amplia Therapeutics Limited (ASX: ATX) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic cancer. FAK also plays a significant role in a number of fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF).
|
|
Shares on Issue: |
194,005,536 Fully Paid Ordinary Shares |
Options on Issue: |
25,439,421 ATXO Listed Options - Ex Price $0.28, Expiry 31 December 2023
7,377,165 Unlisted Options (at varying exercise prices and expiry dates)
|
Target Market Determination: ATXO Options
|
The Company has made a Target Market Determination in respect of ATXO Listed Options - Ex Price $0.28, Expiry 31 December 2023 which can be viewed here.
|
|
Market Listings:
|
Australian Securities Exchange (ASX Code: ATX)
|
|
Directors:
|
Dr Warwick Tong, Chairman, Non-Executive Director Dr Chris Burns, CEO and Managing Director Dr Robert Peach, Independent Non-Executive Director Ms Jane Bell, Independent Non-Executive Director
|
|
Management:
|
Dr Chris Burns, CEO and Managing Director Mr Hamish George, Chief Financial Officer Dr Rhiannon Jones, Chief Operating Officer Mr Andrew Cooke, Company Secretary
|
|
Registered Office: |
Level 17 350 Queen Street Melbourne VIC 3000 Australia
|
|
Auditors: |
Grant Thornton Audit Pty GPO Box 4736 Melbourne 3001 Australia
|
|